Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Figure 3

Efficacy of axitinib and crizotinib in intact and castrated tumor bearing mice by bioluminescence imaging. (A) Bioluminescence measurement of treatment groups on day 34 in intra-tibial VCaP tumor model in intact mice. (B) PSA levels during the course of treatment in intact mice bearing intra-tibial VCaP-Luc tumor. (C) Bioluminescence measurement of treatment groups on day 34 in intra-tibial VCaP tumor model in castrated mice. PSA levels in all groups of castrated mice were below level of detection (data not shown). *p < 0.01, compared to vehicle group. Error bar represents SEM of n = 10mice/group.

Back to article page
\